Inaxaplin
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuric Kidney Disease
Conditions
Proteinuric Kidney Disease
Trial Timeline
Feb 4, 2025 → Dec 30, 2026
NCT ID
NCT06794996About Inaxaplin
Inaxaplin is a phase 2 stage product being developed by Vertex Pharmaceuticals for Proteinuric Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06794996. Target conditions include Proteinuric Kidney Disease.
What happened to similar drugs?
1 of 1 similar drugs in Proteinuric Kidney Disease were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06794996 | Phase 2 | Recruiting |
Competing Products
4 competing products in Proteinuric Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aliskiren + Valsartan | Novartis | Approved | 35 |
| VX-147 + Placebo | Vertex Pharmaceuticals | Phase 2/3 | 45 |
| MZE829 | Maze Therapeutics | Phase 2 | 36 |
| sparsentan + No sparsentan | Travere Therapeutics | Phase 1 | 30 |